XTalks

JULY 25, 2023

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). How Does Cyfendus Work? mL for intramuscular injection.

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

XTalks

OCTOBER 16, 2020

Inmazeb is a combination of three different antiviral monoclonal antibodies. Related: First Ebola Vaccine Cleared by European Commission. “We Inmazeb was developed through Regeneron’s proprietary ‘rapid response’ VelocImmune technology and associated VelociSuite technologies for producing fully human monoclonal antibodies.

Antibody 98

Antibody Drugs Clinical Trials Clinical Trials 98

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Pharmaceutical Technology

JULY 22, 2022

In addition, immunity against the infection is found to wane for both previously infected individuals and the vaccinated. Kai Kupferschmidt, a science journalist, shared an article on the rising measles cases worldwide. Measles is highly contagious and therefore is more visible when vaccine levels decline, the article noted.

Vaccination 130

Vaccination Vaccine Life Science Immune Response 130

Drug Discovery World

APRIL 25, 2024

The market for cell line development is currently rising due to an increased focus by the life sciences sector on biopharmaceuticals and targeted therapies. With the pharmaceutical sector increasingly focused on targeted treatments such as antibodies, developers will be more dependent on cell lines.

Development 59

Development Protein In-Vivo Life Science 59

XTalks

MAY 29, 2024

In its acquisitions, J&J also acquired antibody-drug conjugate (ADC) developer Ambryx and cardiac med tech Laminar along with more than 50 smaller, early-stage licensing deals and partnerships. billion to acquire Telavant for an anti-TL1A antibody, an inflammatory bowel disease candidate ready for Phase III trials.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92